Multifunctional drugs for head injury
Vink, Robert, and Nimmo, Alan J. (2009) Multifunctional drugs for head injury. Neurotherapeutics, 6 (1). pp. 28-42.
|PDF (Published Version) - Registered users only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://www.sciencedirect.com.elibrary./s...
Summary: Traumatic brain injury (TBI) remains one of the leading causes of mortality and morbidity worldwide in individuals under the age of 45 years, and, despite extensive efforts to develop neuroprotective therapies, there has been no successful outcome in any trial of neuroprotection to date. In addition to recognizing that many TBI clinical trials have not been optimally designed to detect potential efficacy, the failures can be attributed largely to the fact that most of the therapies investigated have been targeted toward an individual injury factor. The contemporary view of TBI is that of a very heterogenous type of injury, one that varies widely in etiology, clinical presentation, severity, and pathophysiology. The mechanisms involved in neuronal cell death after TBI involve an interaction of acute and delayed anatomic, molecular, biochemical, and physiological events that are both complex and multifaceted. Accordingly, neuropharmacotherapies need to be targeted at the multiple injury factors that contribute to the secondary injury cascade, and, in so doing, maximize the likelihood of a successful outcome. This review focuses on a number of such multifunctional compounds that have shown considerable success in experimental studies and that show maximum promise for success in clinical trials. Key Words: Neurotrauma, statins, progesterone, erythropoietin, cyclosporin, toll-like receptors, magnesium, dexanabinol, bradykinin, substance P, minocycline, thyrotropin releasing hormone.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||neurotrauma, statins, progesterone, erythropoietin, cyclosporin, toll-like receptors, magnesium, dexanabinol, bradykinin, substance P, minocycline, thyrotropin releasing hormone|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1115 Pharmacology and Pharmaceutical Sciences > 111502 Clinical Pharmacology and Therapeutics @ 50%|
11 MEDICAL AND HEALTH SCIENCES > 1109 Neurosciences > 110999 Neurosciences not elsewhere classified @ 50%
|SEO Codes:||92 HEALTH > 9202 Health and Support Services > 920204 Evaluation of Health Outcomes @ 100%|
|Deposited On:||23 Oct 2009 10:24|
|Last Modified:||13 Feb 2011 04:38|
Last 12 Months: 1
|Citation Counts with External Providers:|
Repository Staff Only: item control page